SAB Biotherapeutics (SABS) Other Accumulated Expenses (2020 - 2026)

SAB Biotherapeutics has reported Other Accumulated Expenses for 7 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 35.68% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 35.68% YoY), and the FY2025 full-year result was $849778.0, up 258.31% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.0 million, up from $849778.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.7 million in Q3 2024, with the low at $64850.0 in Q2 2024.
• Historically, Other Accumulated Expenses has averaged $522075.3 across 5 years, with a median of $364478.0 in 2023.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 76.29% — and 2025, when it surged 978.08%.
• SAB Biotherapeutics' Other Accumulated Expenses stood at $513110.0 in 2022, then dropped by 28.97% to $364478.0 in 2023, then slumped by 34.93% to $237164.0 in 2024, then soared by 258.31% to $849778.0 in 2025, then rose by 18.64% to $1.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.0 million (Q1 2026), $849778.0 (Q4 2025), and $649957.0 (Q3 2025), per Business Quant data.